A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : BC / bromocriptine

[Related PubMed/MEDLINE]
Total Number of Papers: 59
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   BC  (>> Co-occurring Abbreviation)
Long Form:   bromocriptine
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 The Synergistic Effect of Raloxifene, Fluoxetine, and Bromocriptine Protects Against Pilocarpine-Induced Status Epilepticus and Temporal Lobe Epilepsy. FT, NPY, PILO, RF, SE, TLE
2018 Metformin inhibits growth and prolactin secretion of pituitary prolactinoma cells and xenografts. AMPK, D2R, MET, PRL, PRLoma
2018 Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-gamma/Adiponectin, Nrf2/PARP-1, and GLP-1. PD, SG, STZ
2014 [The influence of two-month treatment with bromocryptine on activity of the adenylyl cyclase signaling system in the myocardium and testes of rats with type 2 diabetes mellitus]. AC, ACSS
2013 Activation of D2 dopamine receptors inhibits estrogen response element-mediated estrogen receptor transactivation in rat pituitary lactotrophs. ER, ERE
2013 Bromocriptine inhibits adipogenesis and lipogenesis by agonistic action on alpha2-adrenergic receptor in 3T3-L1 adipocyte cells. alpha2-AR, D2R
2012 Nanoparticulate lipid dispersions for bromocriptine delivery: characterization and in vivo study. bar test, cryo-TEM, MADs, NLCs, PCS, SdFFF
2011 Bromocriptine increased operant responding for high fat food but decreased chow intake in both obesity-prone and resistant rats. DA, DIO, FSA, OM, PR, S5B
2011 Defining CYP3A4 structural responses to substrate binding. Raman spectroscopic studies of a nanodisc-incorporated mammalian cytochrome P450. ERY, RR, TST
10  2010 Bromocriptine and dopamine mediate independent and synergistic apoptotic pathways in pituitary cells. DA
11  2010 Obesity-resistant S5B rats showed greater cocaine conditioned place preference than the obesity-prone OM rats. CPP, D2R, DA, OM
12  2009 Bromocriptine administration reduces hyperphagia and adiposity and differentially affects dopamine D2 receptor and transporter binding in leptin-receptor-deficient Zucker rats and rats with diet-induced obesity. D2R, DA, DAT, DIO
13  2009 Bromocriptine induces parapoptosis as the main type of cell death responsible for experimental pituitary tumor shrinkage. ---
14  2009 Clinical profile and long term follow up of children and adolescents with prolactinomas. PRL
15  2007 Effect of prolactin and bromocriptine on the population of prostate neuroendocrine cells from intact and cyproterone acetate-treated rats: stereological and immunohistochemical study. CA, CT, NECs, PL, Vep
16  2006 The effect of selective sst1, sst2, sst5 somatostatin receptors agonists, a somatostatin/dopamine (SST/DA) chimera and bromocriptine on the "clinically non-functioning" pituitary adenomas in vitro. SST/DA
17  2004 Implication of pituitary vasoactive intestinal peptide in dopaminergic inhibition of estrogen-induced pituitary hyperplasia and vascular endothelial growth factor expression. DES, PRL, VA, VIP
18  2004 The effect of octreotide and bromocriptine on expression of a pro-apoptotic Bax protein in rat prolactinoma. DES, OCT, PRL, RIA
19  2002 Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. BMI
20  2001 Anti-tumoral action of octreotide and bromocriptine on the experimental rat prolactinoma: anti-proliferative and pro-apoptotic effects. AI, BrdU, DES, OCT, PRL, RIA, s.c
21  2001 Bromocriptine and the expression of c-myc and c-fos in human prolactinomas. ---
22  2001 Effects of dopaminergic drugs on inflammatory bowel disease induced with 2,4-dinitrofluorbenzene in BALB/c mice. DA, DNFB, DP, IBD
23  2001 The effect of prolactin and bromocriptine on human peripheral immune status. PRL
24  1999 Bromocriptine/SKF38393 treatment ameliorates dyslipidemia in ob/ob mice. BW, FFA, LPL, TG, VLDL
25  1999 Prolactin protects against diabetes induced by multiple low doses of streptozotocin in mice. IFN-gamma, IL-1, PRL, STZ
26  1998 Hormone secretion by cell culture of human GH-PRL secreting pituitary adenomas: effects of bromocriptine. GH, PRL
27  1998 Surgical indication after bromocriptine therapy on giant prolactinomas: effects and limitations of the medical treatment. ---
28  1997 Dopamine and sympathoadrenal activity in man. BP, DA, HF, HR, LF, NE, nu, PL, SA
29  1997 Inhibitory effects of bromocriptine on vascular smooth muscle cell proliferation. FCS, HAoSMC, PKC, PMA, VSMC
30  1996 Autoparacrine action of vasoactive intestinal peptide on dopaminergic control of prolactin secretion. AP, DA, mRNA, VIP, VIP-At
31  1995 Effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors: in vitro culture studies. CG, PRL
32  1995 In vivo effect of cabergoline, a dopamine agonist, on estrogen-induced rat pituitary tumors. CG, PRL
33  1994 Effects of bromocriptine in Huntington chorea. Case report. BP, FLZ, HVA
34  1994 Lactogenic actions of different growth hormone preparations in pregnant and lactating rats. oPRL, rhGH
35  1994 [Non-puerperal mastitis: a disease without end? (Results of a long-term study)]. NPM
36  1993 Prolactin suppression during pre and post-implantation periods on rat uterine glucosamine synthase activity. ---
37  1993 Restoration of lactation in bromocriptine-treated rats by prolactin replacement: comparison of constant versus pulsatile infusion and intrahepatic versus intrajugular routes of delivery. PRL
38  1993 [Prolactin producing adenoma]. MR, PRL
39  1992 Combined bromocriptine and growth hormone (GH) treatment in GH-deficient children with macroprolactinoma in situ. GH
40  1992 Cytocidal effects of bromocriptine, somatostatin analog, and heat on growth hormone-secreting pituitary adenoma in vitro. GH, PRL, SMS
41  1992 Lethal effects of the combination of hyperthermia and bromocriptine or a somatostatin analogue on normal pituitary cells and pituitary tumour cells. ---
42  1992 [A case of prolactinoma presenting with CSF rhinorrhea and CSF otorrhea during bromocriptine therapy]. CSF, PRL
43  1991 Effect of bromocriptine in patients with apomorphine-responsive erectile impotence: an open study. ---
44  1990 Influence of metoclopramide and bromocriptine upon the growth of human and murine neuroblastoma cells. MCP, NB
45  1989 Perifusion studies of bromocriptine-treated and untreated macroprolactinomas: effects of dopamine, bromocriptine and TRH. ---
46  1989 The addition of bromocriptine to long-term dopa therapy in Parkinson's disease. ---
47  1989 [Dihydroergotoxine mesylate in the treatment of functioning pituitary adenoma]. ---
48  1988 Antagonism of behavioral effects of bromocriptine by prolactin in female cats. PRL
49  1988 Effects of bromocriptine on prolactin cellular hypertrophy, proliferation and secretory activity in diethylstilbestrol-induced pituitary tumors. DES, PRL
50  1987 Metabolite involvement in the behavioral effects of bromocriptine in cats. ---
51  1986 Effect of bromocriptine treatment on the fibrous tissue content of prolactin-secreting and nonfunctioning macroadenomas of the pituitary gland. ---
52  1985 Follow-up of children born of bromocriptine-treated mothers. ---
53  1984 Effects of different dopaminergic antagonists on bromocriptine-induced inhibition of norepinephrine release. BP
54  1984 Long-lasting behavioral effects of bromocriptine in cats. ---
55  1984 Tolerance to the behavioral effects of bromocriptine in cats. ---
56  1983 Dopaminergic stimulation of pituitary but not hypothalamic estrogen receptors in ovariectomized rats. alpha-MT, AP, DA, ER, MBH
57  1983 [Pneumocephalus induced by bromocriptine treatment in male prolactinoma--a case report]. ---
58  1981 Central effects of dopamine and bromocriptine on vasopressin release and blood pressure. DA
59  1980 Effects of prolactin suppression on hypogonadism im patients on maintenance haemodialysis. HD, PRL